Management calls this an inflection, then says it is comfortable with the $4.51 consensus that already prices it in.
Thesis: WBA owns no bottleneck. The PBM sets reimbursement and WBA absorbs it, so the core has zero pricing power while the margin expansion story rests entirely on private label at 16% penetration. Meanwhile the $3.5B Summit bet and widening healthcare EBITDA losses are funded by a retail engine running AOI down 32.8%. The entire bull case is a second half that has not started.
Verdict: HOLD — Conviction: MEDIUM
Catalyst: Q3 print showing generic procurement savings recovering and reimbursement headwind easing, with mid-20s H2 EPS growth tracking on schedule.
Key Risk: The H2 acceleration fails to materialize. Every guidance pillar (procurement savings, reimbursement relief, script recapture, COVID lap) is deferred to a half that has not begun, and 1,900 stores are still on shortened hours exiting the year.
The Tell: CFO Kehoe volunteered, unprompted: 'if we stare out consensus, which I think is at 451, we're pretty comfortable with where that's sitting.' A CFO who is comfortable with consensus is telling you there is no beat coming. Guidance of $4.45 to $4.65 brackets $4.51 with the inflection already priced.
Friction Level: MODERATE_FRICTION — Both sides agree on the numbers: comp scripts +0.2% reported, COVID vaccines -80%, tests -90%, US retail AOI -32.8%, healthcare EBITDA loss widening to -$109M. Disagreement is over whether the second-half bridge (reimbursement easing to ~85% of prior year, generic procurement recovery, 98% contracts locked) delivers the guided mid-20s H2 EPS growth or is another back-loaded promise.
Report not found
The report data is no longer available. Please return to the archive.